142 related articles for article (PubMed ID: 25013419)
21. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
22. CD99 and HLA-II immunostaining in breast cancer tissue and their correlation with lymph node metastasis.
Baccar A; Ferchichi I; Troudi W; Marrakchi R; Ben Hmida N; Jebini S; Mrad K; Ben Romdhane K; Benammar Elgaaied A
Dis Markers; 2013; 34(5):363-71. PubMed ID: 23481630
[TBL] [Abstract][Full Text] [Related]
23. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].
Chao Y; Fan L; Gao XY; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):115-121. PubMed ID: 33554807
[TBL] [Abstract][Full Text] [Related]
24. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
25. Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases.
Zhang PJ; Barcos M; Stewart CC; Block AW; Sait S; Brooks JJ
Mod Pathol; 2000 Apr; 13(4):452-8. PubMed ID: 10786814
[TBL] [Abstract][Full Text] [Related]
26. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
[TBL] [Abstract][Full Text] [Related]
27. [Clinical Features and Prognostic Factors of Patients with Multiple Myeloma].
Gong YY; Yan XS; Wang YM; Pan JL; Zhai YY; Chen SN; Liu DD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):772-780. PubMed ID: 34105471
[TBL] [Abstract][Full Text] [Related]
28. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma.
Sheth N; Yeung J; Chang H
Leuk Res; 2009 Oct; 33(10):1357-60. PubMed ID: 19201468
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
30. CD99 is a novel prognostic stromal marker in non-small cell lung cancer.
Edlund K; Lindskog C; Saito A; Berglund A; Pontén F; Göransson-Kultima H; Isaksson A; Jirström K; Planck M; Johansson L; Lambe M; Holmberg L; Nyberg F; Ekman S; Bergqvist M; Landelius P; Lamberg K; Botling J; Ostman A; Micke P
Int J Cancer; 2012 Nov; 131(10):2264-73. PubMed ID: 22392539
[TBL] [Abstract][Full Text] [Related]
31. Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry.
Firsova MV; Mendeleeva LP; Kovrigina AM; Solovev MV; Savchenko VG
BMC Cancer; 2020 Apr; 20(1):346. PubMed ID: 32321465
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model.
Lee BH; Park Y; Kim JH; Kang KW; Lee SJ; Kim SJ; Kim BS
Sci Rep; 2020 Jul; 10(1):12641. PubMed ID: 32724129
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.
Rasche L; Röllig C; Stuhler G; Danhof S; Mielke S; Grigoleit GU; Dissen L; Schemmel L; Middeke JM; Rücker V; Schreder M; Schetelig J; Bornhäuser M; Einsele H; Thiede C; Knop S
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1988-1996. PubMed ID: 27590108
[TBL] [Abstract][Full Text] [Related]
34. The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation.
Witte HM; Bonorden B; Riecke A; Biersack H; Steinestel K; Merz H; Feller AC; Bernard V; Fetscher S; von Bubnoff N; Gebauer N
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32283706
[No Abstract] [Full Text] [Related]
35. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.
Wader KF; Fagerli UM; Børset M; Lydersen S; Hov H; Sundan A; Bofin A; Waage A
Histopathology; 2012 Feb; 60(3):443-51. PubMed ID: 22276607
[TBL] [Abstract][Full Text] [Related]
37. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
38. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
39. Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma.
Xu J; Yu N; Zhao P; Wang F; Huang J; Cui Y; Ding H; Yang Y; Gao Y; Pan L; Chang H; Wu Y; Xiang B; Gong Y; Shuai X; Hou L; Xie L; Niu T; Liu T; Zhang L; Liu W; Zhang W; Qu Y; Lin W; Zhu Y; Zhao S; Zheng Y
Front Oncol; 2021; 11():694331. PubMed ID: 34268123
[TBL] [Abstract][Full Text] [Related]
40. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
